Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No

This publication has 16 references indexed in Scilit:

• Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin
  Circulation, 2003
• Suboptimal Monitoring and Dosing of Unfractionated Heparin in Comparative Studies with Low-Molecular-Weight Heparin
  Annals of Internal Medicine, 2003
• An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial
  Thrombosis Research, 2003
• Is Impaired Renal Function a Contraindication to the Use of Low-Molecular-Weight Heparin?
  Archives of internal medicine (1960), 2002
• Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis
  Annals of Internal Medicine, 1999
• Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin
  Clinical and Laboratory Haematology, 1999
• Aging and Venous Thromboembolism Influence the Pharmacodynamics of the Anti-Factor Xa and Anti-thrombin Activities of a Low Molecular Weight Heparin (Nadroparin)
  Thrombosis and Haemostasis, 1998
• Heparin Therapy in Pediatric Patients
  Seminars in Thrombosis and Hemostasis, 1997
• Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
  The American Journal of Medicine, 1996
• A Prospective Study of the Value of Monitoring Heparin Treatment with the Activated Partial Thromboplastin Time
  New England Journal of Medicine, 1972